Shinpoong Pharmaceutical신풍제약
019170 · KOSPI · ₩019170 · 신풍제약
₩8,350▼ ₩60 (0.71%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 42.7% | 43.7% | 37.0% | 40.1% | 37.3% | 40.9% |
| Operating margin | 1.1% | 6.1% | −9.3% | −23.7% | −16.3% | −7.6% |
| Net margin | −0.3% | 3.8% | −7.0% | −28.6% | −16.9% | −6.1% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +1.9% | +6.1% | +10.4% | −4.3% | +10.6% | — |
| Operating income growth | −81.1% | +169.7% | +56.8% | −39.3% | −137.8% | — |
| Net income growth | −109.2% | +157.4% | +73.2% | −62.0% | −205.4% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −0.3% | 3.4% | −5.8% | −19.1% | −10.3% | −3.2% |
| Return on assets | −0.7% | 2.4% | −4.4% | −16.1% | −9.3% | −2.9% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 31.8% | 30.2% | 32.5% | 29.3% | 9.3% | 10.6% |
| Net debt to equity | −22.1% | −6.1% | −1.7% | −5.7% | −8.6% | −9.8% |
| Current ratio | 285.7% | 309.0% | 249.6% | 260.4% | 723.5% | 816.1% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Shinpoong Pharmaceutical / 신풍제약 / 019170 / KRX:019170
Source: KRX statistical information